UroGen Pharma saw a welcome improvement to its Relative Strength (RS) Rating on Monday, with an upgrade from 65 to 73.
Can You Really Time The Stock Market?
This unique rating tracks technical performance by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.
Over 100 years of market history shows that the market's biggest winners tend to have an RS Rating of over 80 in the early stages of their moves. See if UroGen Pharma can continue to show renewed price strength and clear that threshold.
While it's not currently an ideal time to invest, see if the stock goes on to offer and clear an appropriate buy point.
UroGen Pharma posted 0% EPS growth in the latest quarterly report, while sales growth came in at 8%.
The company earns the No. 184 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and ACADIA Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Technical Action?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
